European Biotech Award Presented to Cancer Drug Specialist

Clinical-stage biotechnology company Genoscience Pharma, dedicated to discovering and developing anticancer drugs, received the Most Innovative European Biotech SME Award for 2018 in the Healthcare category at EuropaBio.
 

The Marseille-based company’s new therapy with an activity against cancer stem cells, is currently in an international Phase 1/2 trial in liver cancer (US and Europe). Genoscience Pharma’s drug candidate has the potential to be combined with any other anti-cancer therapy (chemotherapy, immunotherapy, targeted therapies and cell-gene therapy).
 

The panel for the ninth edition of the EuropaBio Most Innovative European Biotech SME Awards, assessed 40 companies from across the EU, acknowledging their outstanding contribution towards tackling significant challenges through the application of biotechnology.
 

“Genoscience Pharma is delighted to receive such recognition of its work. We truly believe we can make the difference in cancer treatment with our innovative discovery, the first clinical-stage oral drug with an action on cancer stem cells. As we continue to face significant financing and regulatory barriers, this prize is an important opportunity to demonstrate our work. It will help us to further develop our technology,” said Philippe Halfon, CEO of Genoscience Pharma. “Cancer is probably the most important challenge for humanity. This recognition is one small step for our company but an important step in the fight against cancer.”
 

“For all the Genoscience Pharma team, this prize is a recognition of our hard work. We are delighted to see our efforts awarded, and this shows that no matter the size of a company, with motivation, strength and passion, we can reach our goals,” said Cindy Khaldi, translational science manager at Genoscience Pharma. “We are now looking forward to being able to spread our innovation worldwide to treat patients.”

For information on the EuropaBio Awards visit www.europabio.org